Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Chicago, IL
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Springfield, IL
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Paducah, KY
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Saint Paul, MN
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Olive Branch, MS
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Olive Branch, MS
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Berlin, NJ
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Berlin, NJ
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
mi
from
Chester, NJ
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
mi
from
Chester, NJ
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Eatontown, NJ
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Summit, NJ
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Summit, NJ
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Toms River, NJ
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Albany, NY
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Latham, NY
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Latham, NY
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Manhasset, NY
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
New Hyde Park, NY
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Tulsa, OK
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Providence, RI
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Austin, TX
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Dallas, TX
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Houston, TX
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
San Antonio, TX
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Bennington, VT
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Bennington, VT
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  10/19/2017
mi
from
Woodville South,
Phase 3 IGIV, 10% in Alzheimer´s Disease
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 10/19/2017
mi
from
Woodville South,
Click here to add this to my saved trials
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Rochester, NY
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Costa Mesa, CA
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Hamden, CT
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Hamden, CT
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Orlando, FL
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Tampa, FL
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
West Palm Beach, FL
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Atlanta, GA
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Easton, MD
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Easton, MD
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Flowood, MS
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Toms River, NJ
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Staten Island, NY
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Hickory, NC
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Portland, OR
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Norristown, PA
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Norristown, PA
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Austin, TX
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Bennington, VT
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Bennington, VT
Click here to add this to my saved trials
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated:  10/23/2017
Clinical Research Facility
mi
from
Waukesha, WI
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status: Enrolling
Updated: 10/23/2017
Clinical Research Facility
mi
from
Waukesha, WI
Click here to add this to my saved trials
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated:  10/23/2017
GSK Investigational Site
mi
from
Litchfield Park, AZ
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated: 10/23/2017
GSK Investigational Site
mi
from
Litchfield Park, AZ
Click here to add this to my saved trials
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated:  10/23/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated: 10/23/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated:  10/23/2017
GSK Investigational Site
mi
from
Little Rock, AR
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated: 10/23/2017
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated:  10/23/2017
GSK Investigational Site
mi
from
Fresno, CA
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Status: Enrolling
Updated: 10/23/2017
GSK Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials